EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

AlzChem Group (ALZCF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of AlzChem Group $102, price $185, upside -44.9%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Basic Materials · US · ISIN DE000A2YNT30

AG AlzChem Group logo Broad data Sep 24, 2026

AlzChem Group

ALZCF · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $101.91 · Strongly overvalued (−44.9%)
!Quality 55/100
✓Healthy Growth (revenue 5y +8.2 %/yr)
!Thin margins · 5.8% net margin (TTM)
✓Low debt · generates free cash flow
✓Wide moat 66/100
Watch AlzChem Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$223.25 $22.77 Fair Value $101.91 Dec 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

57‑month range $22.77 – $223.25 · fair‑value band $66.75 – $142.30 · the $184.90 price screens above the $101.91 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding.

Show more

AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries. This segment manufactures composite materials and adhesives, as well as silicon nitride for ceramics; and photovoltaic modules in the solar industry. The Basics & Intermediates segment produces raw materials for specialty chemicals; and products for agriculture and metallurgy, as well as intermediates for the chemical industry that are produced from lime, carbon, and electricity. This segment also engages in the production and sale of guanidine salts as a raw material for agrochemicals and active pharmaceutical ingredients. The Other & Holding segment provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. It offers products and services to agricultural sector under the CALCIUM CYANAMIDE PERLKA, EMINEX, DORMEX, ALZOGUR, SITOFEX, and BREAK-THRU brands; animal nutrition sector under the CREAMINO brands; human nutrition sector under the CREAPURE, CREAVITALIS, LIVADUR, and ALIPURE brands; pharma sector under the GUANIDINE SALTS " BIOSELECT brand; fine chemicals sector under the GUANIDINSALZE -BIOSELECT, CYANAMIDE, DICYANDIAMIDE, GUANAMINE, NITRILES, MELFLOCK and ALZOFIX, THIOUREA, and NITROGUANIDINE brands; metallurgy sector under the CAD, CALCIPRO, and CALZOT brands, as well as technical gases and calcium carbide; renewable energy sector under the DYHARD and SILZOT brands; and custom synthesis, such as toll micronization and manufacturing. AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.

Stock analysis

AlzChem Group (ALZCF) currently trades at $184.90, while our model-based Fair Value estimate is $101.91, 44.9% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $100.68 per share, and 0 of the 24 models we run sit above the $184.90 price.

Bear case: the Asset-Based group reads lowest at $19.09, and 24 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $66.75 (bear) to $142.30 (bull), the price of $184.90 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Basic Materials sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

AlzChem Group reported revenue of €562M in FY2025 versus €422M in FY2021, a compound +7.4%/yr. Reported net income was €63.4M in FY2025, compounding +23.1%/yr from FY2021.

Key figures

Market cap $2.1B · P/E ratio 24.1 · P/S ratio 2.72 · EPS (TTM) $7.67 · Dividend yield 0.9% · Net margin 11.3% · Return on equity 27.3% · Return on assets (EBIT) 17.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 18% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at −45%, ALZCF screens richer than that median.

Fair Value models

Bear $66.75 Fair Value $101.91 Bull $142.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($5.80 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $50.24 $70.30 $98.07 81
Growth DCF $51.32 $69.66 $93.85 79
5Y EBITDA Exit $71.46 $112.89 $159.69 75
All 24 models by family
DCF Models
FCF DCF $50.24 $70.30 $98.07 81
5Y Revenue Exit $59.96 $92.25 $132.45 72
5Y EBITDA Exit $71.46 $112.89 $159.69 75
5Y P/E Exit $70.75 $111.62 $152.81 71
10Y Revenue Exit $53.94 $81.70 $116.85 67
10Y EBITDA Exit $62.81 $95.41 $136.41 68
10Y P/E Exit $62.38 $94.56 $131.48 64
Earnings-Based
Graham-Dodd $47.97 $119.46 $154.92 65
PEG = 1.0 $21.78 $31.11 $40.44 57
EPV $63.20 $72.53 $80.58 74
Dividend Discount
Gordon GGM $17.76 $32.04 $50.10 67
DDM Multi-Stage $17.76 $26.40 $35.41 67
Multiples
P/E Multiple $89.94 $119.92 $149.90 63
P/S Multiple $70.29 $93.72 $117.16 58
P/B Multiple $64.10 $85.47 $106.83 55
EV/EBIT $100.73 $132.94 $165.15 66
EV/EBITDA $95.34 $125.75 $156.17 67
EV/Revenue $69.72 $97.83 $125.95 54
Asset-Based
NCAV (Graham) $14.24 $19.09 $28.49 54
Growth DCF
Growth DCF $51.32 $69.66 $93.85 79
Rev-Margin DCF $59.96 $92.47 $127.65 73
Economic Profit
Residual Income $40.10 $49.15 $75.02 75
ROIC Compounder $65.80 $78.96 $92.79 72
Growth Earnings
Growth-Adj P/E $70.47 $100.68 $130.88 67

Open the full fair value analysis →

Notify me when ALZCF reaches fair value

Put ALZCF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 55/100

Of which business quality 57 · Market factors (momentum, volatility) 57

Profitability 64
Margins and returns on capital today
Quality Growth 23
Are margins and returns improving?
Cashflow 56
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 16
Disciplined investing over empire-building
Low Volatility 70
Calm price path (market factor)
Momentum 51
Price trend over the last 3–12 months (market factor)
52W Momentum 53
Distance to the 52-week high (market factor)
Net Issuance 86
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 76/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic). Over 10 years: +5.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +22.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+21.9%
Dividend (yield on the price)0.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 15%
⚠ Revenue per share shrinking 27.5%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Rate on operating basis: 2025 sits 84% above its own trend.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +17.6% a year for the price and +10.1% for the forecasts.
Forecast 2026 (sales)+7.8%
Forecast 2027 (sales)+16.4%
Projected 2028 (sales)+14.6%
Projected 2029 (sales)+12.8%
Projected 2030 (sales)+11.0%

ALZCF screens overvalued: fair value 45% below the price. Compare with Linde plc →

Compare AlzChem Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 699 stocks

Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −49.7% · Below median
Profitability
Return on equity (TTM) 27.3% · Top 25%
Return on assets 10.2% · Top 25%
Net margin (TTM) 5.8% · Above median
Operating margin (TTM) 16.4% · Top 25%
Growth and dividend
Revenue growth 4.0% · Below median
Dividend yield (TTM) 0.9% · Below median
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (TTM) 24.1× · Pricier than median
P/B 8.28× · Priciest 25%
P/S (TTM) 5.66× · Priciest 25%
P/FCF 54.1× · Priciest 25%
EV/EBITDA 44.1× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Linde plc LIN $474.65 $441.72 −7%
The Sherwin-Williams Company SHW $330.44 $151.68 −54%
Ecolab Inc ECL $274.58 $96.56 −65%
Air Products and Chemicals, Inc APD $279.19 $121.30 −57%
Nan Ya Plastics Corporation 1303 238.00 TWD 234.23 TWD −2%
Givaudan SA GIVN CHF 3,360 CHF 1,527 −55%
Wanhua Chemical Group 600309 ¥69.45 ¥68.03 −2%
DSM-Firmenich AG DSFIR CHF 92.30 CHF 29.70 −68%
Asian Paints Limited ASIANPAINT ₹2,444 ₹1,479 −39%
PPG Industries, Inc PPG $104.67 $76.98 −26%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AlzChem Group · Fair Value
$101.91 −45%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "AlzChem Group Fair Value". https://www.fairvalue-calculator.com/stock/ALZCF

Frequently asked questions

Is AlzChem Group (ALZCF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $101.91 versus the last price from Sep 25, 2026 of $184.90, about −45% upside (overvalued).
What is the fair value of ALZCF?
Our model-based fair value for AlzChem Group is $101.91 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $184.90.
What is the quality score of ALZCF?
AlzChem Group has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AlzChem Group (ALZCF)?
Our model-based price target is the fair value of $101.91 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $66.75, optimistic scenario $142.30. It is a calculation from audited fundamentals, not an analyst target.
What is the AlzChem Group stock forecast for 2026?
Our models put fair value at $101.91, about −45% upside versus the last price from Sep 25, 2026 of $184.90 (overvalued). Cautious scenario $66.75, optimistic scenario $142.30. The calculation is refreshed regularly with new filings.
What is the revenue of AlzChem Group (ALZCF)?
AlzChem Group reported trailing-twelve-month revenue of about €375M (latest available figure, as of Sep 24, 2026).
Does AlzChem Group pay a dividend?
AlzChem Group currently shows a dividend yield of about 0.86% relative to its recent price (as of Sep 24, 2026).
What growth is priced into AlzChem Group (ALZCF)?
For today's price to be fair in a discounted-cash-flow model, AlzChem Group would have to grow free cash flow by +20.2 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of ALZCF use?
Our models discount AlzChem Group at 8.7 %: a base by market capitalisation (mid), damped by beta 0.58, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AlzChem Group that is +20.2 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has AlzChem Group (ALZCF) delivered so far?
Over the past 5 years revenue at AlzChem Group grew +8.2 % a year. The price currently implies +20.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AlzChem Group (ALZCF) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into AlzChem Group (+20.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AlzChem Group (ALZCF)?
The free-cash-flow yield on the price is 2.36 %: that much free cash flow AlzChem Group produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AlzChem Group (ALZCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AlzChem Group it is $101.91 per share (as of Sep 24, 2026), against a price of $184.90. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is AlzChem Group stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ALZCF trades above its calculated fair value: price $184.90, fair value $101.91, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALZCF?
No. The price is what the market pays today ($184.90); the fair value is what the company's own numbers justify ($101.91). For AlzChem Group the two are $82.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is AlzChem Group worth?
The market values AlzChem Group at about $2.1B (market capitalisation, as of Sep 24, 2026). Per share that is $184.90; our models calculate a fair value of $101.91 per share.
What do the bullish and bearish scenarios say about ALZCF?
Our models span a range for AlzChem Group: cautious scenario $66.75, base $101.91, optimistic $142.30 per share (as of Sep 24, 2026, price $184.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALZCF?
AlzChem Group trades at a price-to-earnings ratio of 24.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $101.91 is built from several models across several years. Other multiples: P/B 8.3, P/S 5.7, EV/EBITDA 44.1.
How solid is the balance sheet of AlzChem Group (ALZCF)?
Balance-sheet figures for AlzChem Group (as of Sep 24, 2026): return on equity 27.3%, debt of 0.14 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is ALZCF from its 52-week high?
AlzChem Group trades at $184.90, about 17% below its 52-week high of $223.25 and 18% above the low of $157.16 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $101.91 is for.
Which stocks are comparable to AlzChem Group?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AlzChem Group stock attractive at the current price?
The data as of Sep 24, 2026: price $184.90, calculated fair value $101.91 (−45%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALZCF calculated?
We run AlzChem Group through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $101.91, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. AlzChem Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AlzChem Group (ALZCF)?
The latest price we hold is from Sep 25, 2026 and stands at $184.90. Our model-based fair value is $101.91, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AlzChem Group right now?
The price sits above even our optimistic bull case ($142.30). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($66.75 to $142.30) leaves room in how you read the outcome.

Key figures of AlzChem Group

How large is the market capitalisation of AlzChem Group (ALZCF)?
The market capitalisation of AlzChem Group is $2.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AlzChem Group (ALZCF)?
The price-to-sales ratio of AlzChem Group is 2.72 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AlzChem Group (ALZCF)?
Earnings per share at AlzChem Group are $7.67 (price ÷ EPS = P/E 24.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of AlzChem Group (ALZCF)?
The dividend yield of AlzChem Group is 0.9% (payout 20.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AlzChem Group (ALZCF)?
The net margin of AlzChem Group is 11.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AlzChem Group (ALZCF)?
The return on equity (ROE) of AlzChem Group is 27.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AlzChem Group (ALZCF)?
On an EBIT basis the return on assets of AlzChem Group is 17.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AlzChem Group (ALZCF)?
The operating margin of AlzChem Group is 16.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AlzChem Group (ALZCF)?
Revenue at AlzChem Group is growing +4.0% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AlzChem Group (ALZCF)?
Earnings per share at AlzChem Group are growing +22.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does AlzChem Group (ALZCF) hold?
AlzChem Group holds more cash than debt, €26.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AlzChem Group in the live analysis

One click puts AlzChem Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.